Data Extraction Template

Published You published about 1 year ago.



Item Settings

Editor

I want to start from scratch



General information



Study ID



Title



Lead author contact details



Country in which the study conducted

1. – United States

2. – UK

3. –

Canada

4

Australia

5. –

Other

+



Notes





Characteristics of included studies





Methods





Aa

Aim of study





Study design

1. –

Randomised controlled trial

2. –

Non-randomised experimental study

3. –

Cohort study

4 _

Cross sectional study

5. –

Case control study

6. –

Systematic review

7. –

Qualitative research

8. -

Prevalence study

9. –

Case series

10. –

Case report

11. -

Diagnostic test accuracy study

12. -

Clinical prediction rule

13. -

Economic evaluation

14. -

Text and opinion

15. –

Other





Start date





End date





Study funding sources





Possible conflicts of interest for study authors



H₂

Participants





Population description





Inclusion criteria





Exclusion criteria





Method of recruitment of participants

1. –

Phone

2. –

Mail

3. –

Clinic patients

4. –

Voluntary

5. –

Other





Total number of participants



Type of Mole

1. –

Complete Mole

2. -

Partial Mole

3. –

Invasive Mole

4. -

Choriocarcinoma

5. –

Placental Site Trophoblastic Tumor

6. –

Epithelioid Trophoblastic Tumor

7. –

Other



Time of Contraception Start

1. –

Immediately following GTD treatment

2. –

After beta-hCG normalization

3. –

Other



Baseline Characteristics



Contraception Beta-hCG Normalization Post-molar GTN **Incident Pregnancies** Adverse Events **Preview General information** Study ID Title Title of paper / abstract / report that data are extracted from Lead author contact details Country in which the study conducted 1. United States 2. UK 3. Canada 4. Australia 5. Other Notes

Characteristics of included studies

Methods

Aim of study		
Study design		
1. Randomised co 2. Non-randomise 3. Cohort study 4. Cross sectional 5. Case control stu 6. Systematic revi 7. Qualitative rese 8. Prevalence stud 9. Case series 10. Case report 11. Diagnostic test 12. Clinical predict 13. Economic evalu 14. Text and opinio	ed experimental study udy ew earch dy accuracy study ion rule uation	ıdy
15. Other		//
Start date		
End date		
	11	
Study funding sources		
	11	
Possible conflicts of inter	rest for study author	ors
	11	
Participants		
Population description		
Inclusion criteria	**	
	1	
Exclusion criteria		

Method of recruitment of participants

12/3/23, 11:05 AM		Davidso	n GTD Contraception		
1. Phon	e				
2. Mail					
3. Clini					
4. Volu	ntary				
5. Other		/1			
Total number of	of participants				
Type of Mole	//				
1. Com	plete Mole				
2. Partia					
3. Invas	sive Mole				
	iocarcinoma				
	ental Site Trophoblastic Tum	or			
	elioid Trophoblastic Tumor				
7. Other	<u>r</u>				
	//				
Time of Contra	aception Start				
1. Imme	ediately following GTD trea	ment			
2. After	beta-hCG normalization				
3. Other	r				
	//				
Baseline Chara	acteristics				
Daseille Chara		no 1 Contracention T	rms 2 Total Danulation	n Additional Notas	
Contraceptio		pe 1 Contraception 1	ype 2 Total Population	n Additional Notes	
_	-				
Age (mea					
Gravidity (1					
Parity (m	ean)				
Contraception					
	Combined Vacinal	Duogastin Con	non Duogostin	Donnion	
	oral Vaginal contraceptive Ring pills	Patch Progestin Cop only pills IU		A Implant Barrier Methods	Other
Number of Participants on Method					
Length of Time on Method (Average)					
Beta-hCG Nor	rmalization				

Mean Time (in days) SD

Combined oral contraceptive pills **Vaginal Ring** Patch **Progestin only pills** Copper IUD **Progestin IUD DMPA Implant Barrier Methods** Other None Post-molar GTN **Number of Participants** Combined oral contraceptive pills **Vaginal Ring Patch Progestin only pills Copper IUD Progestin IUD DMPA Implant Barrier Methods** Other None **Incident Pregnancies Number of Participants** Combined oral contraceptive pills **Vaginal Ring Patch Progestin only pills Copper IUD Progestin IUD DMPA**

Implant

Number of Participants

Barrier Methods

Other

None

Adverse Events

Adverse	Number of	Adverse	Number of	Adverse	Number of
Event Type	Participants	Event Type	Participants	Event Type	Participants
1	Participants	2	Participants	3	Participants

Combined oral contraceptive pills

Vaginal Ring

Patch

Progestin only pills

Copper IUD

Progestin IUD

DMPA

Implant

Barrier Methods

Other

None

Feedback & Support

Find your answer, fast.

We've got a new Knowledge base that answers many frequently asked questions. Why not try that first?

View the knowledge base OR Send us an email